ArticleCell reports2012
CD8(+) T cells from mice transnuclear for a TCR that recognizes a single H-2K(b)-restricted MHV68 epitope derived from gB-ORF8 help control infection.
Article in Cell reports, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 21 citations in OpenAlex.
- Rab8a restores diverse innate functions in CD11cNature communications · 2024Article
- A CombinatorialBio-protocol · 2021Article
- Induction of antigen-specific tolerance by nanobody-antigen adducts that target class-II major histocompatibility complexes.Nature biomedical engineering · 2021Article
- ModelingOncoimmunology · 2021Article
- A Mouse Model of PPRV Infection for Elucidating Protective and Pathological Roles of Immune Cells.Frontiers in immunology · 2021Article
- Divergent Effects of a Transient Corticosteroid Therapy on Virus-Specific Quiescent and Effector CD8Frontiers in immunology · 2019Article
- Article
- Herpesviruses: Harmonious Pathogens but Relevant Cofactors in Other Diseases?Frontiers in cellular and infection microbiology · 2018Review
- Transnuclear CD8 T cells specific for the immunodominant epitope Gra6 lower acute-phase Toxoplasma gondii burden.Immunology · 2016Article
- Article
- Article
- Transnuclear TRP1-specific CD8 T cells with high or low affinity TCRs show equivalent antitumor activity.Cancer immunology research · 2013Article
- A catalytically inactive mutant of the deubiquitylase YOD-1 enhances antigen cross-presentation.Blood · 2013Article
- Sortase-mediated modification of αDEC205 affords optimization of antigen presentation and immunization against a set of viral epitopes.Proceedings of the National Academy of Sciences of the United States of America · 2013Article
- Can the triumph of mRNA vaccines against COVID-19 be extended to other viral infections of humans and domesticated animals?Microbes and infectionArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 2 countries.
Funding
Abstract
To study the CD8(+) T cell response against a mouse γ-herpes virus, we generated K(b)-MHV-68-ORF8(604-612)RAG(-/-) CD8(+) T cell receptor transnuclear (TN) mice as a source of virus-specific CD8(+) T cells. K(b)-ORF8-Tet(+) CD8(+) T cells, expanded in the course of a resolving MHV-68 infection, served as a source of nucleus donors. Various in vivo and ex vivo assay criteria demonstrated the fine specificity and functionality of TN cells. TN cells proliferated extensively in response to viral infection, helped control viral burden, and exhibited a phenotype similar to that of endogenous K(b)-ORF8-Tet(+) cells. When compared to OT-1 cells, TN cells displayed distinct properties in response to lymphopenia and cognate antigen stimulation, which may be attributable to the affinity of the TCR expressed by the TN cells. The availability of MHV-68-specific CD8(+) TCR TN mice provides a new tool for investigating aspects of host-pathogen interactions unique to γ-herpes viruses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.